Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc is positioned favorably due to its successful regulatory interactions with both the FDA and the UK MHRA, which have clarified pathways for accelerated approval of its lead candidate, OST-HER2, in the treatment of metastatic osteosarcoma. The company's innovative use of a HER2 bioengineered Listeria platform has shown promise in enhancing immune responses, which is critical for improving outcomes in osteosarcoma patients. Additionally, OS Therapies' plans to advance its OS Animal Health subsidiary through a public transaction further diversify its portfolio and potential revenue streams, enhancing the company's overall market outlook.

Bears say

OS Therapies Inc faces significant challenges in advancing its treatment options for osteosarcoma due to the disease's poor response to receptor-level HER2 inhibition and the nature of its immunological characteristics. The genetic instability of osteosarcoma, coupled with its status as an immunologically "cold" tumor, indicates limited efficacy for the company’s therapeutic approaches that rely on antibody biology. These fundamental scientific barriers raise concerns about the potential for successful commercialization and market penetration of OS Therapies' products, negatively impacting future financial projections.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.